---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-004873"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:15:20.943474+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# INM-901 shows statistically significant reduction in neuroinflammation in long-term Alzheimer's model

## Summary
- INM-901 dose-dependently and significantly reduced pro-inflammatory cytokines TNF-α, IL-1β, and INF-γ.
- High dose group showed statistically significant reduction in neurodegeneration biomarker NfL in plasma.
- mRNA data showed reduction of neuroinflammatory genes GFAP, CD-33, TLR-2 in brain, supporting study results.
- Company will complete analyses of receptor engagement, neuritogenesis, and neuroprotection in coming weeks.

## SEC filing metadata
- accession: 0001213900-25-004873
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025004873/0001213900-25-004873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025004873/ea0228190-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-004873
- JSON: https://secwatch.observer/filing/0001213900-25-004873.json
- Plain text: https://secwatch.observer/filing/0001213900-25-004873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.